<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Secukinumab on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/secukinumab/</link><description>Recent content in Secukinumab on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Thu, 13 Aug 2026 05:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/secukinumab/index.xml" rel="self" type="application/rss+xml"/><item><title>REPLENISH: Secukinumab for Polymyalgia Rheumatica</title><link>https://rheumatologydigest.org/posts/replenish-secukinumab-pmr/</link><pubDate>Thu, 13 Aug 2026 05:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/replenish-secukinumab-pmr/</guid><description>It doubles sustained remission, but 59% still miss the endpoint and half still need escape steroid — an advance on an inadequate standard, not a fix.</description></item></channel></rss>